Want to see HYFT full AI Analyst Report?
HYFT Stock Chart & Stats
$1.33
--
Market closed
$1.33
--
Day’s Range― - ―
52-Week Range$0.99 - $3.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)288.79K
Market Cap
$68.20M
Enterprise Value$67.57
Total Cash (Recent Filing)$14.18M
Total Debt (Recent Filing)$3.55M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Jul 22, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding46,711,864
10 Day Avg. Volume203,250
30 Day Avg. Volume288,791
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.85
Price to Sales (P/S)0.82
P/FCF Ratio-2.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside275.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$20.47M
Bulls Say, Bears Say
Bulls Say
Recurring Platform ContractThe first one-year enterprise Lens AI contract marks a structural move from project work to contracted, recurring revenue. Recurring monthly contracts improve revenue quality, enable predictable cash flow, support margin leverage as usage scales, and create a platform sales motion with higher lifetime value.
Proprietary Platform & Partner ProgramsHYFT’s patented biological representation and integrated wet‑lab engines, plus 20+ partner programs and an extensive publication/patent record, create durable IP and ecosystem advantages. This sticky partner network and unique data layer raise barriers to entry and underpin repeated discovery mandates and licensing.
Revenue Acceleration & U.S. ExpansionMulti‑quarter revenue growth and a doubling of U.S. sales demonstrate durable commercial traction from North American investments. Sustained top‑line acceleration supports scale economics, validates go‑to‑market strategy, and increases odds of converting contracts into higher‑margin recurring streams over time.
Bears Say
High Cash Burn & Negative FCFPersistent negative operating and free cash flow materially erode flexibility and create ongoing financing dependency. Even with recent cash on hand, sustained burn increases dilution risk, forces potentially dilutive financings or asset monetization, and can constrain commercial and R&D pacing over the coming months.
Operating Losses & Negative MarginsDespite improving gross margins, operating expenses remain high versus revenue, keeping EBIT/EBITDA and net margins negative. This structural cost profile means scale is required to reach breakeven; absent meaningful revenue growth or cost discipline, losses will persist and limit free cash generation.
Preclinical Pipeline & Financing UncertaintyA significant portion of program value depends on preclinical readouts and then successful asset‑level financing. These are structural gating events: negative or delayed readouts or slow financing would materially postpone or reduce realized value, increasing execution risk and prolonging reliance on external capital.
MindWalk Holdings News
HYFT FAQ
What was Mindwalk Holdings Corp.’s price range in the past 12 months?
Mindwalk Holdings Corp. lowest stock price was $0.99 and its highest was $3.25 in the past 12 months.
What is Mindwalk Holdings Corp.’s market cap?
Mindwalk Holdings Corp.’s market cap is $68.20M.
When is Mindwalk Holdings Corp.’s upcoming earnings report date?
Mindwalk Holdings Corp.’s upcoming earnings report date is Jul 22, 2026 which is in 2 days.
How were Mindwalk Holdings Corp.’s earnings last quarter?
Mindwalk Holdings Corp. released its earnings results on Mar 12, 2026. The company reported -$0.057 earnings per share for the quarter, missing the consensus estimate of -$0.039 by -$0.019.
Is Mindwalk Holdings Corp. overvalued?
According to Wall Street analysts Mindwalk Holdings Corp.’s price is currently Undervalued.
Does Mindwalk Holdings Corp. pay dividends?
Mindwalk Holdings Corp. does not currently pay dividends.
What is Mindwalk Holdings Corp.’s EPS estimate?
Mindwalk Holdings Corp.’s EPS estimate is -0.05.
How many shares outstanding does Mindwalk Holdings Corp. have?
Mindwalk Holdings Corp. has 46,711,864 shares outstanding.
What happened to Mindwalk Holdings Corp.’s price movement after its last earnings report?
Mindwalk Holdings Corp. reported an EPS of -$0.057 in its last earnings report, missing expectations of -$0.039. Following the earnings report the stock price went up 2.344%.
Which hedge fund is a major shareholder of Mindwalk Holdings Corp.?
Currently, no hedge funds are holding shares in HYFT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MindWalk Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (275.94% Upside)
$5.00 (275.94% Upside)
Blogger Sentiment
Bullish
HYFT Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-46.01%
Trailing 12-Months
Company Description
Mindwalk Holdings Corp.
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.
HYFT Stock 12 Month Forecast
Average Price Target
$5.00
▲(275.94% Upside)
Technical Analysis
XBiotech
―
Relmada Therapeutics
―
PMV Pharmaceuticals
―
Werewolf Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
8.29% Insiders
0.14% Mutual Funds
6.42% Other Institutional Investors
84.84% Public Companies and
Individual Investors